Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine inhalation - Vectura

Drug Profile

Apomorphine inhalation - Vectura

Alternative Names: VR 004; VR 040; VR 400

Latest Information Update: 06 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vectura
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Erectile dysfunction; Female sexual dysfunction; Parkinson's disease

Most Recent Events

  • 01 Sep 2011 Apomorphine inhalation - Vectura is still available for licensing. http://www.vectura.com
  • 31 Mar 2011 Vectura completes a phase II trial in Parkinson's disease in the UK (EudraCT2005-005120-13)
  • 11 Jun 2010 Vectura's inhaled apomorphine product is still in Phase-II trials for Parkinson's disease in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top